Eckert & Ziegler and Ablaze Pharmaceuticals signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a.^177Lu). Eckert & Ziegler will serve as the supplier for Ablaze's clinical trial and research activities utilizing Lutetium-177. Ablaze is currently developing several Lutetium-based drug products for targeted radiotherapy (TRT).

In the TRT approach, a radioisotope such as lutetium-177 is combined with tumor-specific drugs, which then deliver the radiating element of the radioisotope into tumor cells to destroy them, while largely sparing surrounding healthy tissue. Apart from Lutetium-177, Eckert & Ziegler supplies international pharmaceutical companies with Gallium-68, Yttrium-90, Actinium-225 and other radioisotopes that are crucial for use in diagnostics and therapy.